{"id":15175,"date":"2022-05-31T09:18:16","date_gmt":"2022-05-31T07:18:16","guid":{"rendered":"https:\/\/ggba.swiss\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/"},"modified":"2023-07-04T13:40:35","modified_gmt":"2023-07-04T11:40:35","slug":"retinai-enters-a-multi-year-software-license-agreement-with-novartis","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/","title":{"rendered":"RetinAI enters a multi-year software license agreement with Novartis"},"content":{"rendered":"\n

Based on machine learning and computer vision, RetinAI<\/a>\u2019s Discovery UNITY platform allows global organizations to aggregate imaging data to improve the understanding of patient populations and outcomes at scale.<\/p>\n

The AI capabilities integrated with the platform speed up data processing with expert-level analysis and insights extraction. Customers can thus apply RetinAI\u2019s most advanced tools to support their research and clinical development pipeline in ophthalmology, accelerating data analytics and research workflows.<\/p>\n

Companies like\u00a0Novartis<\/a>\u00a0can use RetinAI\u2019s platform to characterize diseases and patient outcomes based on at-scale data organization, data aggregation and applied AI from regulatory-approved and AI research models for diseases in ophthalmology. The platform\u2019s AI models include applications in age-related macular degeneration (including geographic atrophy), diabetic retinopathy, diabetic macular rdema, retinal vein occlusion and glaucoma.<\/p>\n

\u201cWe are very excited to expand our existing relationship with Novartis and see them as an important partner in implementing the future of digital precision medicine. We believe RetinAI\u2019s UNITY platform will redefine how data analysis is performed in drug development, creating opportunities for more cost-effective, target-based research in discovery and clinical trial design,\u201d said Carlos Ciller, CEO of RetinAI.<\/p>\n

The platform is CE-marked and has received clearance from the U.S. Food and Drugs Administration.<\/p>\n","protected":false},"excerpt":{"rendered":"

Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year software license agreement for Discovery UNITY.<\/p>\n","protected":false},"author":3,"featured_media":15176,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[893,930,911],"class_list":["post-15175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-artificial-intelligence","tag-digital-health","tag-pharma"],"acf":[],"yoast_head":"\nRetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year software license agreement for Discovery UNITY.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-31T07:18:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:40:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"RetinAI enters a multi-year software license agreement with Novartis\",\"datePublished\":\"2022-05-31T07:18:16+00:00\",\"dateModified\":\"2023-07-04T11:40:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\"},\"wordCount\":216,\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Pharma\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\",\"name\":\"RetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg\",\"datePublished\":\"2022-05-31T07:18:16+00:00\",\"dateModified\":\"2023-07-04T11:40:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RetinAI enters a multi-year software license agreement with Novartis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/","og_locale":"en_US","og_type":"article","og_title":"RetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area","og_description":"Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year software license agreement for Discovery UNITY.","og_url":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2022-05-31T07:18:16+00:00","article_modified_time":"2023-07-04T11:40:35+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#article","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"RetinAI enters a multi-year software license agreement with Novartis","datePublished":"2022-05-31T07:18:16+00:00","dateModified":"2023-07-04T11:40:35+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/"},"wordCount":216,"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg","keywords":["Artificial Intelligence","Digital Health","Pharma"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/","url":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/","name":"RetinAI enters a multi-year software license agreement with Novartis - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage"},"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg","datePublished":"2022-05-31T07:18:16+00:00","dateModified":"2023-07-04T11:40:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Novartis-630x380-1-3.jpeg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/en\/retinai-enters-a-multi-year-software-license-agreement-with-novartis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"RetinAI enters a multi-year software license agreement with Novartis"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/en\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=15175"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15175\/revisions"}],"predecessor-version":[{"id":17165,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15175\/revisions\/17165"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/15176"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=15175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=15175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=15175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}